Steris Plc (NYSE:STE) – KeyCorp lowered their Q3 2018 EPS estimates for Steris Plc in a report issued on Wednesday. KeyCorp analyst M. Mishan now expects that the medical equipment provider will post earnings per share of $1.06 for the quarter, down from their prior estimate of $1.08. KeyCorp has a “Overweight” rating and a $101.00 price target on the stock. KeyCorp also issued estimates for Steris Plc’s Q4 2018 earnings at $1.21 EPS.

Steris Plc (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.01). Steris Plc had a net margin of 5.59% and a return on equity of 11.49%. The company had revenue of $634.20 million during the quarter, compared to analyst estimates of $629.02 million. During the same quarter in the previous year, the business posted $0.89 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. ILLEGAL ACTIVITY WARNING: “Steris Plc Forecasted to Post Q3 2018 Earnings of $1.06 Per Share (STE)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/07/steris-plc-forecasted-to-post-q3-2018-earnings-of-1-06-per-share-ste.html.

A number of other research firms also recently weighed in on STE. Zacks Investment Research downgraded shares of Steris Plc from a “buy” rating to a “sell” rating in a research note on Monday. Raymond James Financial, Inc. raised their price target on shares of Steris Plc from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Finally, BidaskClub downgraded shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $93.25.

Steris Plc (NYSE STE) traded down $1.43 on Monday, hitting $87.20. 344,969 shares of the stock were exchanged, compared to its average volume of 390,178. Steris Plc has a one year low of $64.37 and a one year high of $93.39. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The firm has a market cap of $7,430.00, a P/E ratio of 22.84 and a beta of 1.31.

Institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. bought a new position in Steris Plc during the 2nd quarter worth approximately $206,000. Van Cleef Asset Management Inc bought a new position in Steris Plc during the 2nd quarter worth approximately $208,000. Cigna Investments Inc. New bought a new position in Steris Plc during the 2nd quarter worth approximately $209,000. BT Investment Management Ltd bought a new position in Steris Plc during the 2nd quarter worth approximately $210,000. Finally, Allegis Investment Advisors LLC bought a new position in Steris Plc during the 2nd quarter worth approximately $251,000. Hedge funds and other institutional investors own 93.91% of the company’s stock.

In other Steris Plc news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $85.69, for a total transaction of $856,900.00. Following the completion of the transaction, the chief executive officer now owns 83,270 shares in the company, valued at approximately $7,135,406.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Michael J. Tokich sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the transaction, the insider now owns 58,588 shares of the company’s stock, valued at approximately $5,390,096. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 205,086 shares of company stock worth $17,965,621. 2.55% of the stock is owned by corporate insiders.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be given a dividend of $0.31 per share. The ex-dividend date is Tuesday, November 21st. This represents a $1.24 annualized dividend and a yield of 1.42%. Steris Plc’s dividend payout ratio is presently 88.57%.

Steris Plc Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Earnings History and Estimates for Steris Plc (NYSE:STE)

Receive News & Stock Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related stocks with our FREE daily email newsletter.